NeuroXess Funding Round

10/28/2026

Venture Equity

$105,000,000

Series B

The funds will be used to support NeuroXess's next stage of development and commercialization of its fully implanted, fully wireless and fully functional brain-computer interface (BCI) system. The company plans to finance multi-centre clinical trials and regulatory registration and approval, expand construction of its large-scale manufacturing facility, develop next-generation BCI products, and explore the integration of brain-computer interface technology with artificial intelligence (BCI+AI). The funding is intended to help advance the technology from clinical testing toward larger-scale medical applications.

Private & Independent

Medical Devices & Instruments

7th Floor, Block A, Hongqiao Chengxin Center, Lane 118, Lian
Shanghai, 201107
CN

NeuroXess is a China-based life sciences and medical technology company founded in 2021. It specializes in implantable flexible Brain-Computer Interface (BCI) technology. The company develops brain-computer interface systems that connect the human brain with computers and other digital devices. Its technology aims to help patients with ALS, spinal cord injuries, stroke, and other neurological disorders restore motor and communication functions. Its solutions include flexible neural electrodes, brain signal decoding systems, proprietary chips, algorithms, and AI-integrated BCI technology.